Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Sarcoma 1Genitourinary 1Gastrointestinal 1Breast 1

Conditions

Stomach Neoplasms 1Sarcoma 1Lung Neoplasms 1Cholangiocarcinoma 1Carcinoma, Transitional Cell 1Carcinoma 1Breast Neoplasms 1

Interventions

Specimen Handling 9Magnetic Resonance Spectroscopy 9Drug Therapy 7Carboplatin 7osimertinib 6Tomography, X-Ray Computed 5Pemetrexed 5Educational Status 5Interviews as Topic 4Early Intervention, Educational 4Cisplatin 4Blood Specimen Collection 4pembrolizumab 3cemiplimab 3atezolizumab 3Radiosurgery 3Methods 3Injections 3Etoposide 3durvalumab 2anlotinib 2aflutinib 2Surgical Procedures, Operative 2Standard of Care 2Radiotherapy 2Radiation 2PM 01183 2Observation 2Nivolumab 2Magnetic Resonance Imaging 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Not yet recruiting × Lung Neoplasms × pemigatinib × Clear all
NCT06551896 2024-08-13

Pemigatinib and Immune Checkpoint Inhibitor Treated FGFR1/2/3 Alteration Advanced Solid Tumor

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Phase 2 Not yet recruiting
30 enrolled
BreastGastrointestinalGenitourinarySarcomaThoracic

Breast Neoplasms, Carcinoma, Carcinoma, Transitional Cell, Lung Neoplasms, Sarcoma, Stomach Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡